Scedosporium Species Infections and Treatments

Journal of Chemotherapy

Volumn 15, Issue SUPPL. 2, 2003, Pages 16-27

  Steinbach, W J ^a,b,c   Perfect, J R ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antifungal therapy; Fungal infection; S. prolificans; Scedosporium species

Indexed keywords

ALBACONAZOLE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; GAMMA INTERFERON; GLYCOPROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; NIKKOMYCIN Z; PENTAMIDINE; PEPTIDOPOLYSACCHARIDE; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; TERBINAFINE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ANTIFUNGAL THERAPY; ANTIMICROBIAL THERAPY; BLOOD CULTURE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG POTENTIATION; FUNGUS IDENTIFICATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOHISTOLOGY; IMMUNOTHERAPY; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; REVIEW; SCEDOSPORIUM; SCEDOSPORIUM PROLIFICANS;

EID: 0346249745     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.supplement-2.16     Document Type: Review

References (126)

1. Walsh TJ, Groll AH. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transplant Infect Dis 1999; 1: 247-261.
2. Saccardo PA. In notae mycologicae, Series XIII. Ann Mycol 1911; 9: 254-255.
3. Shear CL. Life history of an undescribed ascomycete isolated from granular mycetoma of man. Mycologica 1922; 14: 239-243.
4. Emmons CW. Allescheria boydii and Monosporium apiospermum. Mycologica 1944; 36: 188-193.
5. Malloch D, Salkin IF. A new species of Scedosporium associated with osteomyelitis in humans. Mycotaxon 1984; 21: 247-255.
6. Hennebert GL, Desai BG. Lomentospora prolificans, a new hyphomycetes from greenhouse soil. Mycotaxon 1974; 1: 45-50.
7. Gueho E, DeHoog GS. Taxonomy of the medical species of Pseudallescheria and Scedosporium. J Mycol Med 1991; 1: 3-9.
8. Vartivarian SE, Anaissie EJ, Bodey GP. Emerging fungal pathogens in immunocompromised patients. Clin Infect Dis 1993; 17 (suppl 2): S487-S491.
9. Tadros TS, Workowski KA, Siegel RJ, Hunter S, Schwartz DA. Pathology of hyalohyphomycosis caused by Scedosporium apiospermum (Pseudallescheria boydii): an emerging mycosis. Human Pathol 1998; 29: 1266-1272.
10. Kwon-Chung KJ, Bennett JE. Pseudallescheriasis and Scedosporium infection. In: Kwon-Chung KJ, Bennett JE, eds. Medical Mycology. Philadelphia, PA: Lea & Febiger, 1992: 678-694.
11. deHoog GS, Marvin-Sikkema FD, Lahpoor GA, Gottschall JC, Prins RA, Gueho E. Ecology and physiology of the emerging opportunistic fungi Pseudallescheria boydii and Scedosporium prolificans. Mycoses 1994; 37: 71-78.
12. Cano J, Guarro J, Mayayo E, Fernandez-Ballart J. Experimental infection with Scedosporium inflatum. J Med Vet Mycol 1992; 30: 413-420.
13. Ruiz-Diez B, Martinez-Suarez JV. Isolation, characterization, and antifungal susceptibility of melanin-deficient mutants of Scedosporium prolificans. Curr Microbiol 2003; 46: 228-232.
14. Salesa R, Burgos A, Ondiviela R, Richard C, Quindos G, Ponton J. Fatal disseminated infection by Scedosporium inflatum after bone marrow transplantation. Scand J Infect Dis 1993; 25: 389-393.
15. Berenguer J, Rodriguez-Tudela JL, Richard C, et al. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium prolificans Spanish Study Group. Medicine (Baltimore) 1997; 76: 256-265.
16. Summerbell RC, Krajden S, Kane J. Potted plants in hospitals as reservoirs of pathogenic fungi. Mycopathologica 1989; 106: 13-22.
17. Wood GM, McCormack JG, Muir DB, et al. Clinical features of human infection with Scedosporium inflatum. Clin Infect Dis 1992; 14: 1027-1033.
18. Idigoras P, Perez-Trallero E, Pineiro L, et al. Disseminated infection and colonization by Scedosporium prolificans: a review of 18 cases, 1990-1999. Clin Infect Dis 2001; 32: e158-165.
19. San Millan R, Quindos G, Garaizar J, Salesa R, Guarro J, Ponton J. Characterization of Scedosporium prolificans clinical isolates by randomly amplified polymorphic DNA analysis. J Clin Microbiol 1997; 35: 2270-2274.
20. Ruiz-Diez B, Martin-Diez F, Rodriguez-Tudela JL, Alvarez M, Martinez-Suarez JV. Use of random amplification of polymorphic DNA (RAPD) and PCR-fingerprinting for genotyping a Scedosporium prolificans (inflatum) outbreak in four leukemic patients. Curr Microbiol 1997; 35: 186-190.
21. Zouhair R, Defontaine A, Ollivier C, et al. Typing of Scedosporium apiospermum by multilocus enzyme electrophoresis and random amplification of polymorphic DNA. J Med Microbiol 2001; 50: 925-932.
22. Williamson ECM, Speers D, Arthur IH, Harnett G, Ryan G, Inglis TJJ. Molecular epidemiology of Scedosporium apiospermum infection determined by PCR amplification of ribosomal intergenic spacer sequences in patients with chronic lung disease. J Clin Microbiol 2001; 39: 47-50.
23. Defontaine A, Zouhair R, Cimon B, et al. Genotyping study of Scedosporium apiospermum isolates from patients with cystic fibrosis. J Clin Microbiol 2002; 40: 2108-2114.
24. Wilson CM, O'Rourke EJ, McGinnis MR, Salkin IF. Scedosporium inflatum: clinical spectrum of a newly recognized pathogen. J Infect Dis 1990; 161: 102-107.
25. Maertens J, Lagrou K, Deweerdt H, et al. Disseminated infection by Scedosporium prolificans: an emerging fatality among hematology patients. Case report and review. Ann Hematol 2000; 79: 304-344.
26. Tapia M, Richard C, Baro J, et al. Scedosporium inflatum infection in immunocompromised haematologicl patients. Br J Haematol 1994; 87: 212-214.
27. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001; 45: 2151-2153.
28. Salkin IF, McGinnis MR, Dykstra MJ, Rinaldi MG. Scedosporium inflatum, an emerging pathogen. J Clin Microbiol 1988; 26: 498-503.
29. Yao M, Messner AH. Fungal malignant otitis externa due to Scedosporium apiospermum. Ann Otol Rhinol Laryngol 2001; 110: 377-380.
30. Farina C, Arosio M, Marchesi G, Amer M. Scedosporium apiospermum post-traumatic cranial infection. Brain Injury 2002; 16: 627-631.
31. Rumelt S, Cohen I, Lefler E, Rehany U. Corneal co-infection with Scedosporium apiospermum and Acanthamoeba after sewage-contaminated corneal injury. Cornea 2001; 20: 112-116.
32. Wu Z, Ying H, Yiu S, Irvine J, Smith R. Fungal keratitis caused by Scedosporium apiospermum: report of two cases and review of treatment. Cornea 2002; 21: 519-523.
33. Taylor A, Wiffen SJ, Kennedy CJ. Post-traumatic Scedosporium inflatum endophthalmitis. Clin Exp Ophthalmol 2002; 30: 47-48.
34. Kiratli H, Uzun O, Kiraz N, Eldem B. Scedosporium apiospermum chorioretinitis. Acta Ophthalmol Scand 2001; 79: 540-542.
35. Kiraz N, Gulbas Z, Akgun Y, Uzun O. Lymphadenitis caused by Scedosporium apiospermum in an immunocompetent patient. Clin Infect Dis 2001; 32: E59-E61.
36. Canet JJ, Pagerols X, Sanchez C, Vives P, Garau J. Lymphocutaneous syndrome due to Scedosporium apiospermum. Clin Microbiol Infect 2001; 7: 648-652.
37. Severo LC, Oliveira F, Garcia CD, Uhlmann A, Londero AT. Peritonitis by Scedosporium apiospermum in a patient undergoing continuous ambulatory peritoneal dialysis. Rev Inst Med Trop Sao Paulo 1999; 41: 263-264.
38. Eckburg PB, Zolopa AR, Montoya JG. Invasive fungal sinusitis due to Scedosporium apiospermum in a patient with AIDS. Clin Infect Dis 1999; 29: 212-213.
39. Machado CM, Martins MA, Heins-Vaccari EM, et al. Scedosporium apiospermum sinusitis after bone marrow transplantation: report of a case. Rev Inst Med Trop Sao Paulo 1998; 40: 321-323.
40. Sobottka I, Deneke J, Pothman W, Heinemann A, Mack D. Fatal native valve endocarditis due to Scedosporium apiospermum (Pseudallescheria boydii) following trauma. Eur J Clin Microbiol Infect Dis 1999; 18: 387-389.
41. O'Bryan TA, Browne FA, Schonder JF. Scedosporium apiospermum (Pseudallescheria boydii) endocarditis. J Infect 2002; 44: 189-192.
42. Steinbach WJ, Schell WA, Miller JL, Perfect JR. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole, caspofungin and local polyhexamethylene biguanide (PHMB). J Clin Microbiol 2003; 41: 3981-5.
43. Horre R, Feil E, Stangel AP, et al. Scedosporiosis of the brain with fatal outcome after traumatization of the foot. Mycoses 2000; 43: 33-36.
44. Swerczek TW, Donahue JM, Hunt RJ. Scedosporium prolificans infection associated with arthritis and osteomyelitis in a horse. J Am Vet Med Assoc 2001; 218: 1800-1802.
45. Salkin IF, Cooper CR, Bartges JW, Kemna ME, Rinaldi MG. Scedosporium inflatum osteomyelitis in a dog. J Clin Microbiol 1992; 30: 2797-2800.
46. Green Jr. WO, Adams TE. Mycetoma in the United States: review and report of seven additional cases. Am J Clin Pathol 1964; 42: 75-91.
47. Le Gouill SL, Morineau N, Miegeville M, Milipied N, Harousseau JL, Moreau P. Pseudallescheria boydii osteoarthritis in a patient with acute lymphoblastic leukemia: a case report. Rev Med Interne 1999; 20: 434-438.
48. Ansari RA, Hindson DA, Stevens DL, Kloss JG. Pseudoallescheria boydii arthritis and osteomyelitis in a patient with Cushing's disease. South Med J 1987; 80: 90-92.
49. Gatto J, Paterson D, Davis L, Lockwood L, Allworth A. Vertebral osteomyelitis due to Pseudallescheria boydii. Pathology 1997; 29: 238-240.
50. Carreter de Granda ME, Richard C, Conde E, et al. Endocarditis caused by Scedosporium prolificans after autologous peripheral blood stem cell transplantation. Eur J Clin Microbiol Infect Dis 2001; 20: 215-217.
51. Bouza E, Munoz P, Vega L, Rodriguez-Creixems N, Berenguer J, Escudero A. Clinical resolution of Scedosporium prolificans fungemia associated with reversal of neutropenia following administration of granulocyte colony-stimulating factor. Clin Infect Dis 1996; 23: 192-193.
52. Kusne S, Ariyanayagam-Baksh S, Strollo DC, Abernethy J. Invasive Scedosporium apiospermum infection in a heart transplant recipient presenting with multiple skim nodules and a pulmonary consolidation. Transplant Infect Dis 2000; 2: 194-196.
53. Bower CPR, Oxley JD, Campbell CK, Archer CB. Cutaneous Scedosporim apiospermum infection in an immunocompromised patient. J Clin Pathol 1999; 52: 846-848.
54. Smith AG, Crain SM, Dejongh C, Thomas GM, Vigorito RD. Systemis pseudallescheriasis in a patient with acute myelocytic leukemia. Mycopathologia 1985; 90: 85-89.
55. Liu K, Howell DN, Perfect JR, Schell WA. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol 1998; 109: 45-54.
56. Bernstein EF, Schuster MG, Stieritz DD, Hecman PC, Uitto J. Disseminated cutaneous Pseduallescheria boydii. Br J Dermatol 1995; 132: 456-460.
57. Ruxin TA, Steck WD, Helm TN, Bergfeld WF, Bolwell BJ. Pseudalleshceria boydii in an immunocompromised host: successful treatment with debridement and itraconazole. Arch Dermatol 1996; 132: 382-384.
58. Miyamoto T, Sasaoka R, Kawaguchi M, et al. Scedosporium apiospermum skin infection: a case report and review of the literature. J Am Acad Dermatol 1998; 39: 498-500.
59. Miele PS, Levy CS, Smith MA, et al. Primary cutaneous fungal infections in solid organ transplantation: a case series. Am J Transplant 2002; 2: 678-683.
60. Campagnaro EL, Woodside KJ, Early MG, et al. Disseminated Pseudallescheria boydii (Scedosporium apiospermum) infection in a renal transplant patient. Transplant Infect Dis 2002; 4: 207-211.
61. Chaveiro MA, Vieira R, Cardoso J, Afonso A. Cutaneous infection due to Scedosporium apiospermum in an immunnosuppressed patient. Eur Acad Dermatol Venereol 2003; 17: 47-49.
62. Munoz P, Marin M, Tornero P, Martin Rabadan P, Rodriguez-Creixems M, Bouza E. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis 2000; 31: 499-501.
63. Meletiadis J, Meis JFGM, Mouton JW, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002; 46: 62-68.
64. Marin J, Sanz MA, Guarro J, et al. Disseminated Scedosporium inflatum infection in a patient with acute myeloblastic leukemia. Eur J Clin Microbiol Infect Dis 1991; 10: 759-761.
65. Ortoneda M, Pastor FJ, Mayayo E, Guarro J. Comparison of the virulence of Scedosporium prolificans strains from different origins in a murine model. J Med Microbiol 2002; 51: 924-928.
66. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917.
67. Revankar SG, Patterson JE, Sutton DA, Pullen R, Rinaldi MG. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis 2002; 34: 467-476.
68. Cimon B, Carrere J, Vinatier JF, Chazalette JP, Chabasse D, Bouchara JP. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2000; 19: 53-56.
69. Beguin H, Nolard N. Mould biodiversity in homes. Air and surface analysis of 130 dwellings. Aerobiologia 1994; 10: 157-166.
70. Gari M, Fruit J, Rousseaux P, et al. Scedosporium (Monosporium) apiospermum: multiple brain abscesses. Sabouraudia 1985; 23: 371-376.
71. Ruchel R, Wilichowski E. Cerebral Pseudallescheria mycosis after near-drowning. Mycoses 1995; 38: 473-475.
72. Torok L, Simon G, Csornai A, Tapai M, Torok I. Scedosporium apiospermum infection imitating lymphocutaneous sporotrichosis in a patient with myeloblastic-monocytic leukaemia. Br J Dermatol 1995; 133: 805-809.
73. Garcia-Arata MI, Otero MJ, Zomeno M, de la Figuera MA, de las Cuevas MC, Lopez-Brea M. Scedosporium apiospermum pneumonia after autologous bone marrow transplantation. Eur J Clin Microbiol Infect Dis 1996; 15: 600-603.
74. Pinto MR, Mulloy B, Haido RM, Travassos LR, Barreto Bergter E. A peptidohamnomannan from the mycelium of Pseudallescheria boydii is a potential diagnostic antigen of this emerging human pathogen. Microbiology 2001; 147: 1499-1506.
75. Kauffman CA, Standard PG, Jalbert M, Kraft DE. Immunohistologic identification of Aspergillus spp. and other hyaline fungi using polyclonal fluorescent antibodies. J Clin Microbiol 1997; 35: 2206-2209.
76. Wedde M, Muller D, Tintelnot K, de Hoog GS, Stahl U. PCR-based identification of clinically relevant Pseudallescheria/Scedosporium strains. Med Mycol 1998; 36: 61-67.
77. Hagari Y, Ishioka S, Ohyama F, Mihara M. Cutaneous infection showing sporotrichoid spread caused by Pseudallescheria boydii (Scedosporium apiospermum): successful detection of fungal DNA in formalin-fixed, paraffin-embedded sections by seminested PCR. Arch Dermatol 2002; 138: 271-272.
78. Sandhu GS, Kline BC, Stockman L, Roberts GD. Molecular probes for diagnosis of fungal infections. J Clin Microbiol 1995; 33: 2913-2919.
79. Cuenca-Estrella M, Ruiz-Diez B, Martinez-Suarez JV, Monzon A, Rodriguez-Tudela JL. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 1999; 43: 149-151.
80. Del Poeta M, Schell WA, Perfect JR. In vitro activity of pneumocandin L-743-872 against a variety of clinically important molds. Antimicrob Agents Chemother 1997; 41: 1835-1836.
81. Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother 1997; 41: 841-843.
82. Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998; 42: 741-745.
83. Meletiadis J, Meis JFGM, Mouton JW, Donnelly JP, Verweij PE. Comparison of NCCLS and 3-(4,5-dimethyl-2-thiazyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J ClinMicrobiol 2000; 38: 2949-2954.
84. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36: 198-202.
85. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950-2956.
86. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dermatiaceous fungi. J Clin Microbiol 2001; 39: 954-958.
87. McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper CRJ, Rinaldi MG. In vitro activity of voriconazole against selected fungi. Med Mycol 1998; 36: 239-242.
88. Barbaric D, Shaw PJ. Scedosporium infection in immunocompromised patients: successful use of liposomal amphotericn B and itraconazole. Med Pedtr Oncol 2001; 37: 122-125.
89. Carrillo-Munoz AJ, Quindos G, Tur C, et al. Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole. Chemotherapy 2000; 46: 235-244.
90. Cunningham R, Mitchell DC. Amphotericin B responsive Scedosporium apiospermum infection in a patient with acute myeloid leukemia. J Clin Pathol 1996; 49: 93-94.
91. Pickles RW, Pacey DE, Muir DB, Merrell WH. Experience with infection by Scedosporium prolificans including apparent cure with fluconazole therapy. J Infect 1996; 33: 193-197.
92. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologica 2001; 150: 101-115.
93. Ponton J, Ruchel R, Clemons KV, et al. Emerging pathogens. Med Mycol 2000; 38: 225-236.
94. Gonzalez G, Tijerina R, Najvar L, et al. Therapeutic efficacy of posaconazole in a murine Pseudallescheria boydii infection [Abstract J-1615] In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, (Chicago, IL), 2001.
95. Meletiadis J, Mouton JW, Rodriguez-Tudela JL, Meis JFGM, Verweij PE. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother 2000; 44: 470-472.
96. Meletiades J, Mouton JW, Meis JFG, Verweij PE, Network E. Comparison of different models to determine the in vitro synergistic interaction between voriconazole and terbinafine against Scedosporium prolificans [Abstract J-126] In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, (Chicago, IL), 2001.
97. Meletiades J, Mouton JW, Meis JFGM, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 2003; 47: 106-117.
98. Walsh TJ, Peter J, McGough DA, Fothergill AW, Rinaldi MG, Pizzo PA. Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother 1995; 39: 1361-1364.
99. Afeltra J, Dannaoui E, Meis JF, Rodriguez-Tudela JL, Verweij PE. In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans. Antimicrob Agents Chemother 2002; 46: 3323-3326.
100. Li RK, Rinaldi MG. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob Agents Chemother 1999; 43: 1401-1405.
101. Gil-Lamaignere C, Roilides E, Maloukou A, Georgopoulou I, Petrikkos G, Walsh TJ. Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 2002; 50: 1027-1030.
102. Gil-Lamaignere C, Maloukou A, Rodriguez-Tudela JL, Roilides E. Human phagocytic cell responses to Scedosporium prolificans. Med Mycol 2001; 39: 169-175.
103. Gil-Lamaignere C, Roilides E, Mosquera J, Maloukou A, Walsh TJ. Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother 2002; 46: 2234-2237.
104. Ortoneda M, Capilla J, Pujol I, et al. Liposomal amphotericin B and granulocyte colony-stimualting factor therapy in a murine model of invasive infection by Scedosporium prolificans. J Antimicrob Chemother 2002; 49: 525-529.
105. Goldberg SL, Geha DJ, Marshall WF, Inwards DJ, Hoagland HC. Successful treatment of simultaneous pulmonary Pseduallescheria boydii and Aspergillus terreus infection with oral itraconazole. Clin Infect Dis 1993; 16: 803-805.
106. Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR, Lutsar I. Voriconazole for the treatment of S. apiospermum and S. prolificans infeection [Abstract 305] In: 38th Infectious Diseases Society of America Meeting, (New Orleans, LA), 2000.
107. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-1131.
108. Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002; 34: 1648-1650.
109. Verweij PE, Cox NJ, Meis JFGM. Oral terbinafine for treatment of pulmonary Pseudallescheria boydii infection refractory to itraconazole therapy. Eur J Clin Microbiol Infect Dis 1997; 16: 26-28.
110. Steinbach WJ, Perfect JR. Newer antifungal therapy for emerging fungal pathogens. Int J Infect Dis 2003; 7: 5-10.
111. Espinel-Ingroff A. Comparison of the E-test with NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi. J Clin Microbiol 2001; 39: 1360-1367.
112. Huczko E, Minassian B, Washo T, Bonner D, Fung-Tomc J. In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates [Abstract J-810] In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, (Chicago, IL), 2001.
113. Hennequin C, Benailly N, Silly C, et al. In vitro susceptibilities to amphotericin B, itraconazole, and miconazole of filamentous fungi isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 1997; 41: 2064-2066.
114. Uchida K, Nishiyama Y, Yokota N, Yamaguchi H. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiot 2000; 53: 1175-1181.
115. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30: 251-255.
116. Girmenia C, Luzi G, Monaco M, Martino P. Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J Clin Microbiol 1998; 36: 1436-1438.
117. Jabado N, Casanova J-L, Haddad E, et al. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin Infect Dis 1998; 27: 1437-1441.
118. Nesky MA, McDougal EC, Peacock JEJ. Pseudallescheria boydli brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system Pseudallescheriasis. Clin Infect Dis 2000; 31: 673-676.
119. Poza G, Montoya J, Redondo C, et al. Meningitis caused by Pseudallescheria boydii treated with voriconazole. Clin Infect Dis 2000; 30: 981-982.
120. Fietz T, Knauf W, Schwartz S, Thiel E. Intramedullary abscess in a patient with disseminated Scedosporium apiospermum infection. Br J Haematol 2003; 120: 724.
121. Talbot TR, Hatcher J, Davis SF, Pierson RN, Barton R, Dummer S. Scedosporium apiospermum pneumonia and sternal wound infection in a heart transplant recipient. Transplantation 2002; 74: 1645-1647.
122. Safdar A, Papadopoulos EB, Young JW. Breakthrough Scedosporium apiospermum (Pseudallescheria boydii) brain abscess during therapy for invasive pulmonary aspergillosis following high-risk allogeneic hematopoletic stem cell transplantation. Scedosporiasis and recent advances in antifungal therapy. Transplant Infect Dis 2002; 4: 212-217.
123. Orchiai N, Shimazaki C, Uchida K, et al. Disseminated infection due to Scedosporium apiospermum in a patient with acute myelogenous leukemia. Leukemia Lymphoma 2003; 44: 369-372.
124. Martino R, Nomdedeu J, Altes A, et al. Successful bone marrow transplantation in patients with previous invasive fungal infections: report of four cases. Bone Marrow Transplant 1994; 13: 265-269.
125. Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003; 22: 111-113.
126. Spielberger RT, Tegtmeier BR, O'Donnell MR, Ito JI. Fatal Scedosporium prolificans (S. inflatum) fungemia following allogeneic bone marrow transplantation: report of a case in the United States. Clin Infect Dis 1995; 21: 1067.